乳腺癌PET/CT的变异与陷阱
本文综述了乳腺癌患者F-18 FDG PET/CT评估中需注意的正常变异与陷阱。FDG-PET不用于乳腺癌初始诊断,局灶性葡萄糖代谢增高提示肿瘤可能但非特异,良性乳腺病变、炎症及其他恶性肿瘤亦可表现为高代谢。乳腺癌代谢活性因肿瘤异质性和亚型差异很大,腋窝淋巴结评估不如前哨淋巴结活检准确,但识别II、III级及胸肌后转移很准确,近期接种疫苗(尤其COVID-19)可致腋窝淋巴结代谢增高。
要点
- FDG-PET不用于乳腺癌初始诊断,局灶性高代谢需进一步评估但特异性有限。
- 乳腺癌代谢活性因肿瘤异质性和亚型差异大,良性病变和炎症也可高代谢。
- 腋窝淋巴结评估不如前哨淋巴结活检准确,但识别II、III级及胸肌后转移准确。
核心结论
- 乳腺癌FDG-PET评估需注意正常变异与陷阱,局灶性高代谢并非乳腺癌特有,良性疾病和炎症也可表现。
研究设计与样本
- 本文为综述,总结乳腺癌患者F-18 FDG PET/CT评估中的正常变异与陷阱。
主要发现
- FDG-PET不用于乳腺癌初始诊断,但乳腺组织局灶性葡萄糖代谢增高高度提示肿瘤性病变,需进一步评估。
- 淋巴瘤、实体瘤转移及炎症改变也可在乳腺或全身其他部位表现为葡萄糖代谢增高。
- 良性乳腺疾病也可表现葡萄糖代谢增高,限制FDG-PET的特异性。
- 乳腺癌代谢活性范围广,归因于肿瘤异质性和乳腺癌亚型,调节肿瘤葡萄糖利用的细胞内信号通路参与这些陷阱。
- FDG-PET评估腋窝淋巴结不如前哨淋巴结操作准确,但识别II和III级腋窝淋巴结转移或胸肌后转移非常准确。
临床怎么用
- 全身FDG-PET用于乳腺癌分期时需特别关注FDG分布的生理性变异,并与配准的解剖影像仔细对比。
- 需注意近期疫苗接种(尤其COVID-19)可常见导致腋窝淋巴结代谢活性增高。
- 现代PET/CT技术常可检出淋巴结非恶性炎症,需结合临床鉴别。
局限性
- 本文为综述,未报告原始研究的设计细节、样本量或定量阈值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There are a number of normal variants and pitfalls which are important to consider when evaluating F-18 Fluorodeoxyglucose (FDG) with Positron Emission Tomography (PET) in breast cancer patients. Although FDG-PET is not indicated for the initial diagnosis of breast cancer, focally increased glucose metabolism within breast tissue represents a high likelihood for a neoplastic process and requires further evaluation. Focally increased glucose metabolism is not unique to breast cancer. Other malignancies such as lymphoma, metastases from solid tumors as well as inflammatory changes also may demonstrate increased glucose metabolism either within the breast or at other sites throughout the body. Importantly, benign breast disease may also exhibit increased glucose metabolism, limiting the specificity of FDG-PET. Breast cancer has a wide range of metabolic activity attributed to tumor heterogeneity and breast cancer subtype. Intracellular signaling pathways regulating tumor glucose utilization contribute to these pitfalls of PET/CT in breast cancer. The evaluation of axillary lymph nodes by FDG-PET is less accurate than sentinel lymph node procedure, however is very accurate in identifying level II and III axillary lymph node metastases or retropectoral metastases. It is important to note that non-malignant inflammation in lymph nodes are often detected by modern PET/CT technology. Therefore, particular consideration should be given to recent vaccinations, particularly to COVID-19, which can commonly result in increased metabolic activity of axillary nodes. Whole body FDG-PET for staging of breast cancer requires specific attention to physiologic variants of FDG distribution and a careful comparison with co-registered anatomical imaging. The most important pitfalls are related to inflammatory changes including sarcoidosis, sarcoid like reactions, and other granulomatous diseases as well as secondary neoplastic processes.
引用
- Kikano EG, Avril S, Marshall H, et al. PET/CT Variants and Pitfalls in Breast Cancers. Semin Nucl Med. 2021. PMID: 34088473. doi:10.1053/j.semnuclmed.2021.04.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。